Thirty years of clinical genetic testing from Salt Lake City — hereditary cancer, oncology genomics, reproductive health, and beyond.
Myriad Genetics
venture active confidence: Medium status: Draft updated 2026-08-11
Summary
Myriad Genetics is a publicly traded molecular diagnostics company headquartered in Salt Lake City, Utah (FY2025 Form 10-K). Myriad helped establish that inherited cancer risk could be tested routinely in clinical care.
Impact
Myriad helped establish that inherited cancer risk could be tested routinely in clinical care. Today its impact is measured through deployed laboratory tests: hereditary cancer panels that inform screening and prevention decisions, tumor genomic profiling that can surface therapy-linked biomarkers, reproductive-health screens for expectant parents, and prostate-cancer tests that aim to clarify aggressiveness.
At Utah scale, Myriad remains one of the state's largest life-sciences employers and a visible anchor of the Wasatch Front genomics cluster alongside university research institutes, ARUP Laboratories, and consumer-genomics companies. The commitment is physical and long-dated: the 10-K describes a West Salt Lake City headquarters of approximately 234,000 square feet of laboratory and office space on a lease running to 2038, and CLIA-certified high-complexity laboratories in Salt Lake City alongside Mason, Ohio and South San Francisco.
What They Are Building
Myriad's current portfolio spans five public-facing health areas:
- Hereditary cancer risk — multi-cancer germline panels (the site references tests covering 11 hereditary cancers, including MyRisk).
- Oncology — germline and tumor genomic tests intended to support screening, treatment selection, and survivorship decisions.
- Reproductive health — carrier screening, prenatal chromosomal testing, and early fetal-sex determination products.
- Urology — Prolaris and related prostate-cancer tests; the site highlights newer Prolaris + AI capabilities combining genomics with digital pathology.
- Mental health — pharmacogenomic testing to inform antidepressant and related medication selection.
The harder-to-see product is the accumulated variant-interpretation, reporting, and laboratory infrastructure behind those menus — plus the payer, provider-education, and health-system integration work required to keep tests in clinical use at scale.
What They Need Now
Likely needs include molecular biologists, bioinformatics engineers, clinical laboratory scientists, variant-curation specialists, regulatory and quality professionals familiar with laboratory-developed tests, health-system partnership managers, and product leaders who can translate genomics into clinician-friendly reports.
For talent matching, Myriad suits scientists and operators who want clinically deployed precision medicine in Utah rather than relocating to Boston or the Bay Area — with the caveat that public-company diagnostics businesses carry payer, competition, and quarterly-volume dynamics that differ from early-stage biotech.
Who Could Help
Useful helpers include FDA and CLIA regulatory counsel, health-system genomics program leaders, payer-relations advisors, clinical laboratory automation experts, and commercial partners that extend test distribution into hospital networks.
Utah Context
Myriad was founded in Salt Lake City in 1991 and remains headquartered there — at 322 North 2200 West on the city's west side, per its FY2025 10-K, not the Research Park address that several third-party directories still carry. Its origins connect to University of Utah human genetics research and the state's unusual genealogical and medical-record infrastructure; see Myriad Genetics BRCA Sequencing and Testing for that historical work story rather than repeating it here.
In the present tense, Myriad is part of Utah's "Genome Valley" cluster — a concentration of genomics, bioinformatics, and diagnostics activity anchored by the University of Utah, ARUP, and neighboring ventures such as BioFire Diagnostics and Ancestry.
Evidence
- Source: Myriad Genetics Form 10-K, Fiscal Year 2025 · https://www.sec.gov/Archives/edgar/data/899923/000089992326000018/mygn-20251231.htm — revenue, net loss, impairments, headcount, headquarters address and square footage, CLIA lab locations
- Official Website: Myriad Genetics · https://www.myriad.com/ — product menu and positioning only; self-reported
See Also
- Myriad Genetics BRCA Sequencing and Testing
- Utah Population Database
- BioFire Diagnostics
- Huntsman Cancer Institute
Open Questions
Employee count and revenue verified against SEC filings— done 2026-08-11 from the FY2025 10-K. Test volume is still unsourced: the filing discusses volumes in risk-factor language rather than publishing a figure, so an investor presentation or the segment tables are the next stop.- The product-portfolio claims on this page still rest on the company's own website. Sourcing them to Item 1 of the 10-K (and the revenue-by-category table, where Hereditary Cancer is the largest line) is what would raise Confidence from Medium to High.
- Two claims recorded from the marketing site in June 2026 — the Prolaris + AI highlight and the comparative-variant-database claim — were not present in the 2026-08-11 fetch. Neither is load-bearing here, but if either is used, date-attribute it.
- How competitive Myriad's oncology and liquid-biopsy offerings are versus peers such as Natera and Guardant is not established from the official website alone.
- CEO and strategy transitions in recent years deserve a sourced leadership timeline; the 8-K series in EDGAR (
https://data.sec.gov/submissions/CIK0000899923.json) is the primary trail. - Whether the FY2025 impairments signal a strategic retreat from Women's Health and Mental Health, or an accounting reset, is not answerable from the filing alone and matters for anyone weighing a job offer in those lines.